

Please type a plus sign (+) inside this box ____

PTO/SB/05 (03-01)

Approved for use through 10/31/2002, OMB 0655,0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE d to respond to a collection of information unless it displays a valid OMB control

Under the Paperwork Reduction Act of 1995, no persons are require	· · · · · · · · · · · · · · · · · · ·	number.					
UTILITY PATENT APPLICATION	Attorney Docket PC009C1						
TRANSMITTAL	Title Nucleic Acids, Proteins, and Antibodies						
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Express Mail Label						
		Box Patent Application					
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application con	ADDRESS						
X Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1 27. X Specification [Total Pages 64] (preferred arrangement set forth below) - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence lisbing, a table, or a computer program listing appendix	8. Nucleotide and/or (if applicable, all r a. X Computer b. Specification S i. X CD	CD-R in duplicate, large table or rogram (Appendix) r Amino Acid Sequence Submission necessary) Readable Form (CRF) Sequence Listing on: -ROM or CD-R (2 copies); or ii. paper ts verifying identity of above copies					
Background of the Invention Brief Summary of the Invention	ACCOMP	ANYING APPLICATIONS PARTS					
- Binef Description of the Drawings (if filed) - Detailed Description - Claim(s)		27 CFD 3 73/h) Stelement					
- Abstract of the Disclosure 4 Drawing(s) (35 U.S.C. 113) [Total Sheets	(when there	is an assignee) Attorney					
5. Oath or Declaration [Total Pages 5	l <u>L</u>	Information Displaceum Coming of IDS					
a Newly executed (original or copy)	13. Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment						
Copy from a prior application (37 CFR 1 63(d))	\ <u>\</u>	eipt Postcard (MPEP 503)					
i DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	15. (Should be so Certified Copy (if foreign protest) 16. Nonpublicati Applicant me 17. X Other: 11.	15. (Should be specifically ifemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Nonpublication Request under 35 U S C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent					
6. X Application Data Sheet See 37 CFR 1.76 (7 pages)		F.R. §§ 1.824 and 1.52(e)					
18. If a CONTINUING APPLICATION, check appropriate box, and Data Sheet under 37 CFR 1.76: X Continuation Divisional Continuation Prior application information: Examiner CI For CONTINUATION or DIVISIONAL APPS only: The entire of under Box 5b, is considered a part of the disclosure of the accordence.	art (CIP) of prior application L. Group / District of the prior application,	09/764,847 Art Unit: 1631 from which an oath or declaration is supplied					
19. CORF	PONDENCE ADDRES	S					
X Customer Number or Bar Code Label	22195	or Correspondence address below					
Name							
Address							
City Sta		Zip Code					
Country Tele	ne	Fax					
Name (Print/Type) Mark J. Hyman	Registration No. (A	Attorney/Agent) 46,789					
Signature MAN H		Date March 7, 2002					

PTO/SB/17 (11-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002 Patent fees are subject to annual revision.		Complete if Known								
		7 10 10 10 10 10 10 10 10 10 10 10 10 10				Not Yet Assigned				
						Herewith				
		First Named Inventor F			Rosen et al.					
		Examiner Name				Not Yet Assigned				
Application claims small entity status. See 37 CFR 1.27		Group Art Unit			Not Yet Assigned					
TOTAL AMOUNT OF PAYMENT (\$) 896.00		Attorney Docket No. PC009C1								
METHOD OF PAYMENT (check all that apply)				FEE	CALCUL	ATION (co	ntinued)			
Check Credit Money Other None	Chart Credit Money Other None 3 ADDITIONAL FEES									
X Deposit Account	l									
Deposit O. 2405	Large Fee	Entity	Smal	I Entity Fee	-					
Account Number 08-3425	Code	Fee (\$)	Code	(\$)		Fee Desc	ription	Fee Paid		
Deposit Liumon Comomo Sciences Inc	105	130	205	65	Surcharge -	- late filing fe	e or oath			
Account Name Human Genome Sciences, Inc.	127					- late provisio	onal filing fee or cove			
The Commissioner is hereby authorized to: (check all that apply)					sheet.					
X Charge fee(s) indicated below X Credit any overpayments Charge any additional fee(s) during the pendency of this	139	130	139	130	•	specification				
application	147	2,520	147	2,520	-		parte reexamination			
Charge fee(s) indicated below, except for the filing fee	112	920*	112	920*	Requesting publication of SIR prior to Examiner action					
to the above-identified deposit account.	113	3 1,840* 113 1,840* Requesting Examiner a				publication o	of SIR after			
FEE CALCULATION	115	110	215	55	Extension fo					
1. BASIC FILING FEE	116	400	216	200			n second month			
Large Entity Small Entity Fee Fee Fee Fee Fee Fee Fee Fee Fee Fe	117	920	217	460		or reply within				
Code (\$) Code (\$) Fee Paid	118	1,440	218	720	Extension fo					
101 740 201 370 Utility filing fee 740 00 106 330 206 165 Design filing fee	128	1,960 320	228 219	980 160	Extension for Notice of Ap					
107 510 207 255 Plant filing fee	120	320	220	160	Filing a brief					
108 740 208 370 Reissue filing fee	121	280	221	140	Request for oral hearing					
114 160 214 80 Provisional filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding					
SUBTOTAL (1) (\$) 740 00	140	110	240	55	Petition to re	evive unavo	oidable			
	141	1,280	241	640		evive - uninte				
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	142	1,280	242	640	=	fee (or reissi	ne)			
Claims below Fee Paid	143									
Total Claims 24 -20** = 4 x 18.00 = 72.00	144 122					rianar				
Claims 4 -3 = 1 x 84.00 = 84.00	123	50	123	50			CFR 1 17(q)			
Multiple Dependent	126	180	126	180	-		on Disclosure Stmt			
Large Entity Small Entity Fee Fee	ĺ		1							
Code (\$) Code (\$) Fee Description	581	40	581	40	Recording each patent assignment per orocerty (times number of procerties)					
103 18 203 9 Claims in excess of 20 102 84 202 42 Independent claims in excess of 3	146	740	246	370	(37 CFR 1.129(a))					
104 280 204 140 Multiple dependent claim, if not paid	149	740	249	370	For each additional invention to be examined (37CFR 1 129(b))					
109 84 209 42 ** Reissue independent claims	179	740	279	370	Request for	Request for Continued Examination (RCE)				
over original patent 110 18 210 9 ** Reissue claims in excess of 20	169	900	169	900		or expedited examination				
and over original patent	Other fee (specify)									
SUBTOTAL (2) (\$) 156 00	*Red	uced by	Basic F	iling Fee	e Paid	SUBTO	TAL (3) (\$)	0.00		
**or number previously paid, if greater; For Reissues, see above	<u> </u>		===					====		
SUBMITTED BY	Regis	tration N	2. 1	. 700			(if applicable)			
Name (Print/Type) Mark J. Hyman	7. Hyman (Attorney/Agent) 40,769						(240) 314-1224			
Signature						Date	March 7, 2002			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Attorney Docket No.: PC009C1

Application Serial No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: Herewith

Examiner: Not Yet Assigned

Title: Nucleic Acids, Proteins, and Antibodies

STATEMENT UNDER 37 C.F.R. § 1.821

Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on compact disc) Sequence Listing submitted herewith.

Respectfully submitted,

Dated: March 7, 2002

Reg. No. 46,789

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 Telephone: (240) 314-1224

Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Attorney Docket No.: PC009C1

Application Serial No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: Herewith

Examiner: Not Yet Assigned

Title: Nucleic Acids, Proteins, and Antibodies

TRANSMITTAL AND SUBMISSION UNDER 37 C.F.R. §§ 1.824 AND 1.52(e)

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §§ 1.821(e) and 1.824, Applicants submit herewith a Sequence Listing satisfying the computer readable format requirements on a compact disc (CD-R) labeled "CRF." Applicants submit concurrently herewith a Statement Under 37 C.F.R. § 1.821.

Additionally, in accordance with 37 C.F.R. §§ 1.52(e), 1.821, and 1.823, Applicants submit herewith a Sequence Listing as an electronic document on two identical compact discs (CD-R). Applicants certify under 37 C.F.R. § 1.52(e)(4) that these two compact discs, labeled "Copy 1" and "Copy 2," are identical. These compact discs, formatted for an IBM-PC machine and compatible with the MS-Windows operating system, each contain the file "PC009C1 seqList.txt" (4,095,326 bytes in size, created March 6, 2002).

Respectfully submitted,

Dated: March 7, 2002

Mark J. Hyman

Reg. No. 46,789

Attorney for Applicants

Human Genome Sciences, Inc.

9410 Key West Avenue Rockville, MD 20850 Telephone: (240) 314-1224

Enclosures